NCT06825663Not yet recruiting
Marker of Brain Insulin Resistance in AD Prognosis
Brain Insulin Resistance Index in Plasma Neuronal Exosomes As Predictive Biomarkers of Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 13 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Basic research data from the literature on the links between cerebral insulin resistance and Alzheimer's disease (AD) suggest that this pathophysiological mechanism is involved at a very early stage in the development of the disease. The insulin receptor (IR) is a tyrosine kinase receptor whose activation by insulin binding leads to autophosphorylation of its IRβ subunits and then of the insulin receptor substrate proteins (IRS-1). The ratio of IRS residues phosphorylated on serine 312 (P(Ser312)-IRS-1) to total phosphorylated IRS or IRS phosphorylated on its tyrosines has been proposed by some authors as an index of insulin resistance in the brain. IRS-1 proteins can be measured in exosomes, and in particular in neuronal exosomes isolated from plasma. It is therefore conceivable to measure this index in these biological samples specifically derived from neurons and available from a simple blood test, in order to determine whether it could be of prognostic interest in patients with mild cognitive impairment (MCI), in particular by making it possible to identify at an early stage patients who are going to convert to AD.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 122 (estimated)
- First submitted
- 10 Feb 2025
- Start date
- 15 Mar 2025
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- Central Hospital, Nancy, France
- Diseases
- Alzheimer disease
- NCT number
- NCT06825663
What you commit to
- Study type: Interventional
- Planned participants: 122
- From 15 Mar 2025 to the primary completion date, 1 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Persons under psychiatric care by virtue of articles L. 3212-1 and L. 3213-1.
Other
- Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
- A person who has converted to clinically proven AD. The fact that an LP to measure AD markers has been performed is not a criterion for inclusion.
- An adult unable to give consent
- Person deprived of liberty by a judicial or administrative decision
- Pregnant women, women in labour or breastfeeding mothers
- Persons staying in a health or social establishment for purposes other than research.
Who the study is looking for
- Men or women aged 18 to 75
- Have been treated for mild cognitive impairment at the Nancy CHRU CMRR for 1 to 2 years
- Person affiliated to a social security scheme or beneficiary of such a scheme
- Person who has received full information on the organisation of the research and has signed an informed consent form
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.